How to buy Edwards Lifesciences Corporation stock | $80.55

Edwards Lifesciences Corporation is a medical devices business based in the US. Edwards Lifesciences Corporation shares (EW) are listed on the NYSE and all prices are listed in US Dollars. Edwards Lifesciences Corporation employs 14,900 staff and has a trailing 12-month revenue of around 0.00.

Edwards Lifesciences Corporation share price

Use our graph to track the performance of EW stocks over time.

Edwards Lifesciences Corporation shares at a glance

• Key figures

Information last updated 2021-05-07.

Latest market close	$80.55
52-week range	$66.23 - $98.11
50-day moving average	$87.81
200-day moving average	$85.08
Wall St. target price	$98.35
PE ratio	68.0133
Dividend yield	N/A (0%)
Earnings per share (TTM)	$1.35

Buy Edwards Lifesciences Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Edwards Lifesciences Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Edwards Lifesciences Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Edwards Lifesciences Corporation price performance over time

Historical closes compared with the close of $80.55 from 2021-03-25

1 week (2021-05-05)	-12.23%
1 month (2021-04-15)	-8.47%
3 months (2021-02-16)	-7.39%
6 months (2020-11-16)	-1.97%

1 year (2020-05-15)	-62.18%
2 years (2019-05-16)	-54.53%
3 years (2018-05-16)	136.42
5 years (2016-05-16)	104

Is Edwards Lifesciences Corporation under- or over-valued?

Valuing Edwards Lifesciences Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Edwards Lifesciences Corporation's P/E ratio

Edwards Lifesciences Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, Edwards Lifesciences Corporation shares trade at around 68x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Edwards Lifesciences Corporation's PEG ratio

Edwards Lifesciences Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3964. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Edwards Lifesciences Corporation's EBITDA

Edwards Lifesciences Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 billion.

The EBITDA is a measure of a Edwards Lifesciences Corporation's overall financial performance and is widely used to measure a its profitability.

Edwards Lifesciences Corporation financials

Revenue TTM	$4.5 billion
Operating margin TTM	29.8%
Gross profit TTM	$3.3 billion
Return on assets TTM	12.54%
Return on equity TTM	19.88%
Profit margin	19.02%
Book value	$7.49
Market capitalisation	$57 billion

TTM: trailing 12 months

Shorting Edwards Lifesciences Corporation shares

There are currently 6.6 million Edwards Lifesciences Corporation shares held short by investors – that's known as Edwards Lifesciences Corporation's "short interest". This figure is 21.5% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting Edwards Lifesciences Corporation shares can be evaluated.

Edwards Lifesciences Corporation's "short interest ratio" (SIR)

Edwards Lifesciences Corporation's "short interest ratio" (SIR) is the quantity of Edwards Lifesciences Corporation shares currently shorted divided by the average quantity of Edwards Lifesciences Corporation shares traded daily (recently around 2.6 million). Edwards Lifesciences Corporation's SIR currently stands at 2.54. In other words for every 100,000 Edwards Lifesciences Corporation shares traded daily on the market, roughly 2540 shares are currently held short.

However Edwards Lifesciences Corporation's short interest can also be evaluated against the total number of Edwards Lifesciences Corporation shares, or, against the total number of tradable Edwards Lifesciences Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edwards Lifesciences Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Edwards Lifesciences Corporation shares in existence, roughly 10 shares are currently held short) or 0.0107% of the tradable shares (for every 100,000 tradable Edwards Lifesciences Corporation shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Edwards Lifesciences Corporation.

Find out more about how you can short Edwards Lifesciences Corporation stock.

Edwards Lifesciences Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Edwards Lifesciences Corporation's total ESG risk score

Total ESG risk: 21.68

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences Corporation's overall score of 21.68 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Edwards Lifesciences Corporation's environmental score

Environmental score: 4.78/100

Edwards Lifesciences Corporation's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Edwards Lifesciences Corporation's social score

Social score: 13.43/100

Edwards Lifesciences Corporation's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Edwards Lifesciences Corporation's governance score

Governance score: 10.96/100

Edwards Lifesciences Corporation's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Edwards Lifesciences Corporation's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences Corporation has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Edwards Lifesciences Corporation was last rated for ESG on: 2019-01-01.

Total ESG score	21.68
Total ESG percentile	24.1
Environmental score	4.78
Environmental score percentile	6
Social score	13.43
Social score percentile	6
Governance score	10.96
Governance score percentile	6
Level of controversy	2

Edwards Lifesciences Corporation share dividends

We're not expecting Edwards Lifesciences Corporation to pay a dividend over the next 12 months.

Have Edwards Lifesciences Corporation's shares ever split?

Edwards Lifesciences Corporation's shares were split on a 3:1 basis on 31 May 2020. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences Corporation shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences Corporation shares which in turn could have impacted Edwards Lifesciences Corporation's share price.

Edwards Lifesciences Corporation share price volatility

Over the last 12 months, Edwards Lifesciences Corporation's shares have ranged in value from as little as $66.23 up to $98.11. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences Corporation's is 1.0856. This would suggest that Edwards Lifesciences Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Edwards Lifesciences Corporation overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. .

Frequently asked questions

• What percentage of Edwards Lifesciences Corporation is owned by insiders or institutions?

  Currently 0.737% of Edwards Lifesciences Corporation shares are held by insiders and 86.091% by institutions.

• How many people work for Edwards Lifesciences Corporation?

  Latest data suggests 14,900 work at Edwards Lifesciences Corporation.

• When does the fiscal year end for Edwards Lifesciences Corporation?

  Edwards Lifesciences Corporation's fiscal year ends in December.

• Where is Edwards Lifesciences Corporation based?

  Edwards Lifesciences Corporation's address is: One Edwards Way, Irvine, CA, United States, 92614

• What is Edwards Lifesciences Corporation's ISIN number?

  Edwards Lifesciences Corporation's international securities identification number is: US28176E1082

• What is Edwards Lifesciences Corporation's CUSIP number?

  Edwards Lifesciences Corporation's Committee on Uniform Securities Identification Procedures number is: 28176E108